Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

BACKGROUND: Since a phase I clinical trial using three HLA-A24-binding peptides from TTK protein kinase (TTK), lymphocyte antigen-6 complex locus K (LY6K), and insulin-like growth factor-II mRNA binding protein-3 (IMP3) had been shown to be promising for esophageal squamous cell carcinoma (ESCC), we...

Descripción completa

Detalles Bibliográficos
Autores principales: Kono, Koji, Iinuma, Hisae, Akutsu, Yasunori, Tanaka, Hiroaki, Hayashi, Naoko, Uchikado, Yasuto, Noguchi, Tsuyoshi, Fujii, Hideki, Okinaka, Kota, Fukushima, Ryoji, Matsubara, Hisahiro, Ohira, Masaichi, Baba, Hideo, Natsugoe, Shoji, Kitano, Seigou, Takeda, Kazuyoshi, Yoshida, Koji, Tsunoda, Takuya, Nakamura, Yusuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403921/
https://www.ncbi.nlm.nih.gov/pubmed/22776426
http://dx.doi.org/10.1186/1479-5876-10-141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403921/
https://www.ncbi.nlm.nih.gov/pubmed/22776426
http://dx.doi.org/10.1186/1479-5876-10-141

Ejemplares similares